Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study

[1] Budman SH(2009)Can abuse deterrent formulations make a difference? Expectation and speculation Harm Reduct J 6 8-217

[2] Grimes Serrano JM(2011)Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions Am J Drug Alcohol Abuse 37 205-16

[3] Butler SF(2018)Oral and non-oral routes of administration among prescription opioid users: pathways, decision-making and directionality Addict Behav 86 11-62

[4] Katz N(2017)Relative preferences in the abuse of immediate-release versus extended-release opioids in a sample of treatment-seeking opioid abusers Pharmacoepidemiol Drug Saf 26 56-26

[5] Dart RC(2016)Prescription opioid misuse, abuse, and treatment in the United States: an update Am J Psychiatry 173 18-18

[6] Bailey E(2008)Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep 10 11-418

[7] Trudeau J(2012)A review of abuse-deterrent opioids for chronic nonmalignant pain P T 37 412-1612

[8] Osgood E(2012)Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers Clin Ther 34 1601-410

[9] Paillard F(1996)Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution J Pharm Sci 85 407-16

[10] Cicero TJ(2014)Pharmacology of opioids and their effects on gastrointestinal function Am J Gastroenterol Suppl 2 9-700

[1] Budman SH(2009)Can abuse deterrent formulations make a difference? Expectation and speculation Harm Reduct J 6 8-217

[2] Grimes Serrano JM(2011)Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions Am J Drug Alcohol Abuse 37 205-16

[3] Butler SF(2018)Oral and non-oral routes of administration among prescription opioid users: pathways, decision-making and directionality Addict Behav 86 11-62

[4] Katz N(2017)Relative preferences in the abuse of immediate-release versus extended-release opioids in a sample of treatment-seeking opioid abusers Pharmacoepidemiol Drug Saf 26 56-26

[5] Dart RC(2016)Prescription opioid misuse, abuse, and treatment in the United States: an update Am J Psychiatry 173 18-18

[6] Bailey E(2008)Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep 10 11-418

[7] Trudeau J(2012)A review of abuse-deterrent opioids for chronic nonmalignant pain P T 37 412-1612

[8] Osgood E(2012)Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers Clin Ther 34 1601-410

[9] Paillard F(1996)Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution J Pharm Sci 85 407-16

[10] Cicero TJ(2014)Pharmacology of opioids and their effects on gastrointestinal function Am J Gastroenterol Suppl 2 9-700